Ziqiang Wang

Chiral chromatography has become the preferred tool for enantiomer separations in the early stages of pharmaceutical development for the purpose of accurately identifying single pure enantiomers with pharmacologic, toxicological, and clinical information, as stipulated by the FDA.1

According to the FDA policy statement, developing stereoisomeric drugs, each enantiomer should be evaluated.